85
Participants
Start Date
October 7, 2020
Primary Completion Date
February 8, 2022
Study Completion Date
February 8, 2022
Al18F-NOTA-octreotide
One intravenous injection of 4 MBq/kg
PET/CT
Patients in part A of the trial will undergo a whole-body PET/CT scan 120 minutes (acceptable range: 105 - 240 minutes) after injection of the tracer. The CT-scan is a low-dose CT that will be acquired for both PET attenuation correction and anatomical information.
PET/MR
Patients in part B of the trial will undergo a whole-body PET/MR scan 120 minutes (acceptable range: 105 - 240 minutes) after injection of the tracer. The MR scan is a fully diagnostic MR requiring intravenous contrast (Dotarem®) injection and Buscopan® administration to minimize bowel movement.
Universitaire Ziekenhuizen Leuven, Leuven
University Hospital, Antwerp
OTHER
University Hospital, Ghent
OTHER
NETwerk, Belgium
UNKNOWN
Universitaire Ziekenhuizen KU Leuven
OTHER